IN2012DN03310A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03310A
IN2012DN03310A IN3310DEN2012A IN2012DN03310A IN 2012DN03310 A IN2012DN03310 A IN 2012DN03310A IN 3310DEN2012 A IN3310DEN2012 A IN 3310DEN2012A IN 2012DN03310 A IN2012DN03310 A IN 2012DN03310A
Authority
IN
India
Prior art keywords
moeties
peptiod
tetrapeptide
tripeptide
dipeptide
Prior art date
Application number
Other languages
English (en)
Inventor
Guido Franzoso
Albert Andrzej Jaxa-Chamiec
Caroline Minli Rachel Low
Simona Maria Monti
Menotti Ruvo
Laura Tornatore
Catherine Jane Tralau-Stewart
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Publication of IN2012DN03310A publication Critical patent/IN2012DN03310A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IN3310DEN2012 2009-10-22 2010-10-22 IN2012DN03310A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0918579.4A GB0918579D0 (en) 2009-10-22 2009-10-22 Gadd45beta targeting agents
PCT/GB2010/001970 WO2011048390A2 (fr) 2009-10-22 2010-10-22 Agents de ciblage de gadd45 bêta

Publications (1)

Publication Number Publication Date
IN2012DN03310A true IN2012DN03310A (fr) 2015-10-23

Family

ID=41426579

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3310DEN2012 IN2012DN03310A (fr) 2009-10-22 2010-10-22

Country Status (14)

Country Link
US (2) US8993717B2 (fr)
EP (2) EP2491051A2 (fr)
JP (2) JP5961113B2 (fr)
KR (1) KR20120099440A (fr)
CN (1) CN102741269B (fr)
AU (1) AU2010309594B2 (fr)
BR (1) BR112012011332B1 (fr)
CA (2) CA2778236A1 (fr)
GB (1) GB0918579D0 (fr)
IL (1) IL219325B (fr)
IN (1) IN2012DN03310A (fr)
MX (1) MX357801B (fr)
RU (2) RU2577311C2 (fr)
WO (1) WO2011048390A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
PL219569B1 (pl) 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
GB201107118D0 (en) 2011-04-27 2011-06-08 Imp Innovations Ltd Method of diagnosis and prognosis
WO2013055051A1 (fr) * 2011-10-14 2013-04-18 서울대학교산학협력단 Nanostructure peptidique et son procédé de production
CA2853791C (fr) 2011-10-28 2017-10-24 Ruey J. Yu Derives n-acyldipeptides et leurs utilisations
US20150038541A1 (en) * 2012-03-19 2015-02-05 Aposignal Bioscience Llc Composition and methods for cell modulation
CN104817616A (zh) * 2014-01-30 2015-08-05 陈光健 寡肽cd02及其制备方法和应用
CN104817618B (zh) * 2014-01-30 2018-07-03 陈光健 寡肽cd01及其制备方法和应用
GB201414542D0 (en) * 2014-08-15 2014-10-01 Imp Innovations Ltd Novel therapy
CN111574585B (zh) * 2019-01-30 2021-10-01 浙江省医学科学院 一种鳕鱼皮寡肽及其分离纯化方法和应用
RU2716258C1 (ru) * 2019-07-30 2020-03-11 Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий Пептидный антагонист нмда-рецептора
KR102417496B1 (ko) * 2019-11-29 2022-07-06 (주)수파드엘릭사 안드로겐 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물
WO2021194228A1 (fr) * 2020-03-23 2021-09-30 주식회사 엘베이스 Composition pharmaceutique pour la prévention ou le traitement du cancer
KR102348728B1 (ko) * 2020-03-23 2022-01-12 주식회사 엘베이스 암의 예방 또는 치료용 약학적 조성물
PH12022553378A1 (en) 2020-06-10 2024-03-25 Univ Leuven Kath Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
WO2022203219A1 (fr) * 2021-03-22 2022-09-29 주식회사 엘베이스 Composition pharmaceutique pour la prévention ou le traitement du cancer
JP7610862B2 (ja) * 2021-03-22 2025-01-09 エル－ベース カンパニー リミテッド がんの予防または治療用薬学的組成物
AU2022306289A1 (en) 2021-07-09 2024-01-18 Aligos Therapeutics, Inc. Anti-viral compounds
IT202100023357A1 (it) * 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica
WO2023043261A1 (fr) * 2021-09-17 2023-03-23 주식회사 엘베이스 Composition pharmaceutique pour améliorer l'effet anticancéreux d'un médicament anticancéreux
US20250213645A1 (en) * 2021-09-17 2025-07-03 L-Base Co., Ltd. Pharmaceutical composition for modulating immune response
KR102494749B1 (ko) * 2021-09-17 2023-02-06 주식회사 엘베이스 암 치료용 cage 저해제에 대한 반응자 특성화 방법
WO2023043816A1 (fr) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Composés antiviraux pour le traitement d'infections à coronavirus, picornavirus et norovirus
KR102786112B1 (ko) * 2021-09-17 2025-03-27 주식회사 엘베이스 항암제의 항암 효과 증진용 약학적 조성물
CN113929737B (zh) * 2021-10-20 2024-07-23 中国科学院香港创新研究院再生医学与健康创新中心 一种多肽及其作为cck受体激动剂/拮抗剂的应用
CN116350746B (zh) * 2023-05-16 2024-03-22 海口桥水联合科技有限责任公司 沙丁鱼肽组合物在治疗过敏性鼻炎的药物中的应用
CN119874809B (zh) * 2025-01-13 2026-04-21 广东工业大学 一类抗氧化肽及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
HU187461B (en) * 1981-10-22 1986-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for producing n-nitrozo-n-bracket-beta-chloroethyl-bracket closed-carbamoyl-peptides of citostatic activity
CA1257199A (fr) 1986-05-20 1989-07-11 Paul Y. Wang Preparation contenant une substance macromoleculaire ayant des proprietes biologiques liberee pendant plusieurs mois in vivo
DE3813989A1 (de) * 1987-04-29 1988-11-10 Hoechst Ag Peptide mit phospholipase a(pfeil abwaerts)2(pfeil abwaerts)-hemmender wirkung
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US5962270A (en) 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
FR2774674B1 (fr) 1998-02-10 2000-03-24 Atochem Elf Sa Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre
US5993414A (en) 1998-04-23 1999-11-30 Medtronic, Inc. Implantable device
US20030162223A1 (en) 1999-10-22 2003-08-28 Lowery David E. Drosophila G protein coupled receptors, nucleic acids, and methods related to the same
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
WO2002092566A1 (fr) * 2001-05-15 2002-11-21 Taisho Pharmaceutical Co.,Ltd. Derives d'arginine
BR0210252A (pt) * 2001-07-13 2004-09-14 Pepharm R & D Ltd Peptìdeos biologicamente ativos
US7354898B2 (en) * 2001-10-02 2008-04-08 University Of Chicago Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
CA2462638A1 (fr) 2001-10-02 2003-04-10 University Of Chicago Procedes et compositions de modulation d'apoptose
KR20060015446A (ko) 2002-08-19 2006-02-17 윤 엔 간 질환의 치료 방법
TW200503747A (en) 2003-04-22 2005-02-01 Avanir Pharmaceuticals Peptide mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
US7084111B2 (en) * 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
WO2006049597A1 (fr) * 2004-10-27 2006-05-11 Avanir Pharmaceuticals Composes derives d'acides amines utilises en tant que modulateurs du transport inverse du cholesterol
SG158899A1 (en) * 2005-01-13 2010-02-26 Univ Wollongong Peptidic compounds
AU2006212922B2 (en) 2005-02-09 2011-04-21 Helix Biomedix Inc. Antimicrobial hexapeptides
US7919468B2 (en) * 2005-04-07 2011-04-05 Centre National De La Recherche Scientifique (C.N.R.S.) Compounds useful as modulators of the proteasome activity
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EP1930017B1 (fr) * 2005-09-29 2012-05-23 Maruha Nichiro Seafoods, Inc. Composition efficace pour la prévention et le traitement d'une pathologie chez l'adulte
JP2007217358A (ja) * 2006-02-17 2007-08-30 Nippon Meat Packers Inc 抗酸化性ペプチド
WO2007117444A2 (fr) * 2006-03-31 2007-10-18 Yinghe Hu Détection de protéines au moyen d'aptamères
US20090312396A1 (en) 2006-07-10 2009-12-17 Astrazeneca Ab Methods for cancer treatment using tak1 inhibitors
AU2007284801A1 (en) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
CN101153053B (zh) * 2006-09-28 2012-02-01 中国医学科学院药物研究所 骨生肽、其制备方法和其药物组合物与用途
EP1964560A1 (fr) 2007-02-28 2008-09-03 Helmholtz-Zentrum für Infektionsforschung GmbH Utilisation d'inhibiteurs de la dégradation du p27 pour le traitement du cancer
DE112009000300T5 (de) 2008-02-08 2011-01-20 Aileron Therapeutics, Inc., Cambridge Therapeutische Peptidomimetische Makrocyclen
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
EP2390662A1 (fr) 2010-05-27 2011-11-30 Erasmus University Medical Center Rotterdam Classification moléculaire de plusieurs myélomes

Also Published As

Publication number Publication date
RU2012120905A (ru) 2013-11-27
WO2011048390A3 (fr) 2011-11-03
KR20120099440A (ko) 2012-09-10
US20150368294A1 (en) 2015-12-24
US8993717B2 (en) 2015-03-31
CN102741269A (zh) 2012-10-17
JP2016166211A (ja) 2016-09-15
JP2013508346A (ja) 2013-03-07
WO2011048390A2 (fr) 2011-04-28
RU2577311C2 (ru) 2016-03-20
MX357801B (es) 2018-07-25
RU2016102083A (ru) 2018-11-20
EP3178836B1 (fr) 2019-12-25
BR112012011332B1 (pt) 2022-07-05
US20120277164A1 (en) 2012-11-01
EP3178836A1 (fr) 2017-06-14
AU2010309594A1 (en) 2012-05-17
CA2778236A1 (fr) 2011-04-28
GB0918579D0 (en) 2009-12-09
US9518083B2 (en) 2016-12-13
AU2010309594B2 (en) 2016-01-07
IL219325B (en) 2019-02-28
MX2012004755A (es) 2012-11-22
EP2491051A2 (fr) 2012-08-29
IL219325A0 (en) 2012-06-28
CA3034860A1 (fr) 2011-04-28
BR112012011332A2 (pt) 2016-11-22
JP5961113B2 (ja) 2016-08-02
CN102741269B (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
IN2012DN03310A (fr)
PH12014500053A1 (en) Proteasome inhibitors
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
PH12012500916B1 (en) Treatments for gastrointestinal disorders
IN2012MN02591A (fr)
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MX366130B (es) Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos.
PH12015500832A1 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
EP4269563A3 (fr) Anticorps anti-gd2
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
PL3208612T3 (pl) Kompozycje i sposoby leczenia chorób o podłożu immunologicznym
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
PH12018500640A1 (en) Optimized monoclonal antibodies agaist tissue factor pathway inhibitor (tfpi)
MX2011007930A (es) Conjugados de insulina cristalina.
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX2011009033A (es) Inhibidores triciclicos de cinasa pirazolopiridina.
IL206834A0 (en) Methods and compositions for oral administration of protein and peptide therapeutic agents
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
PH12012501389A1 (en) Hedgehog inhibitors
MX2010002667A (es) Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
WO2010135521A3 (fr) Compositions et procédés pour le traitement et le diagnostic de la grippe
EP1993523A4 (fr) Compositions et méthodes destinées au traitement de troubles liés à l'agrégation des protéines
WO2014039074A3 (fr) Compositions thérapeutiques et méthodes associées
EP4218786A3 (fr) Opiorphine destinée à être utilisée comme agent analgésique